Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bipolar Androgen Therapy in mCRPC
NCT06305598Phase 1Active, not recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Dec 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of testosterone cypionate in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Androgen receptor activity up to 2 years. Started Dec 2024; status: active, not recruiting.
02
Drugs
testosterone cypionate
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06305598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06305598.